title: European drug market entries 2015 with new mechanisms of action.
abstract: In this article, we consider the new drugs approved for the European market in 2015. We present a summary of the new mechanisms of action introduced and highlight three new mechanisms of action with a potentially high future impact: PCSK9 inhibition (alirocumab (Praluent®) and evolocumab (Repatha®)) for hypercholesterolaemia, neprilysin inhibition (sacubitril in combination with valsartan (Entresto®)) for heart failure, and interleukin-5 inhibition (mepolizumab (Nucala®)) for asthma.
authors.affiliation: Leiden University Medical Centre, Leiden, the Netherlands.
authors.forename: Titus W P
authors.initials: TW
authors.lastname: van den Heuvel
authors.affiliation: Leiden University Medical Centre, Leiden, the Netherlands and CEO, Centre for Human Drug Research, Leiden, the Netherlands.
authors.forename: Adam F
authors.initials: AF
authors.lastname: Cohen
authors.affiliation: Leiden University Medical Centre, Leiden, the Netherlands and director of education, Centre for Human Drug Research, Leiden, the Netherlands rrissmann@chdr.nl.
authors.forename: Robert
authors.initials: R
authors.lastname: Rissmann
mesh_terms: D018927:Anti-Asthmatic Agents / Q000378:metabolism / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized / Q000378:metabolism / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000378:metabolism / Q000494:pharmacology; D017277:Drug Approval; D004345:Drug Industry; D005060:Europe; D006801:Humans; D000960:Hypolipidemic Agents / Q000378:metabolism / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D018927:Anti-Asthmatic Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents; C434107:mepolizumab; C577155:evolocumab; C571059:alirocumab
keywords: Pharmacology; asthma; drug mechanisms; first in class; heart failure; hypercholesterolaemia; market approval